Evidence map›Paper›PMID 32523361›Full record

ArticleInfection and drug resistance2020

Characterization of Extended-Spectrum β-Lactamase-Producing Uropathogenic

Mehrdad Halaji, Shahrzad Shahidi, Abdolamir Atapour, Behrooz Ataei, Awat Feizi, Seyed Asghar Havaei

Abstract read
In one paragraph

Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Trial
  2. UropathogenicAntibiotics (Basel, Switzerland) · 2026
    Review
  3. Article
  4. UropathogenicInternational journal of molecular sciences · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. UropathogenicMicroorganisms · 2023
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Prevalence of ESBL and AmpC genes inNew microbes and new infections · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mehrdad HalajiDepartment of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-4576-8203
Shahrzad ShahidiIsfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Abdolamir AtapourIsfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Behrooz AtaeiInfectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Awat FeiziDepartment of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID 0000-0002-1930-0340
Seyed Asghar HavaeiDepartment of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of this study was to investigate the antimicrobial susceptibility pattern and the presence of ESBLs among the uropathogenic MATERIALS AND

methodsA total of 111 pure cultures of UPEC isolates were collected from 65 and 46 of non-KTP and KTPs with UTIs. The pattern and ESBL production of the strains were evaluated. PCR reaction to detect the presence of

resultsThe results revealed that most of UPEC isolates obtained from KTPs and control group were resistant to trimethoprim/sulfamethoxazole (84.8% vs 46.2%), while carbapenems (100% sensitivity) were the most effective against UPEC isolates. ESBL-producing strains were significantly more frequent in KTPs compared with control group (43.5% vs 23.1%,

conclusionOur results showed a high proportion of multidrug-resistant and ESBL-producing isolates, which most of them harbor blaCTX-M. A significant high co-resistance to different classes of antibiotics was reported from ESBL-producing UPEC from KTPs, which remains a serious clinical challenge.

Indexed as

ESBLKTPPCRUTIs

Identifiers

PMID32523361
PMCPMC7237106

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.